Tacit science
Every cell carries machinery to cut and stitch RNA. Tacit redirects this machinery, called the spliceosome, to repair genes at the RNA level.
Tacit’s programs are in preclinical development. No Tacit therapy is approved for clinical use, and safety and efficacy in humans have not been established. Development outcomes and timelines remain subject to further testing and regulatory review.
The mechanism
A faulty gene is read into a faulty RNA. Tacit's proprietary Splicing-Directed Repair™ technology redirects the cell's own splicing machinery to swap the faulty section out of that RNA and replace it with a correct one. The intent is that the cell then makes a normal protein from its own gene, matched in space, time and level to what the native gene would have produced.
01
An RNA carries a mutation
02
Mutated region bound by the SDR RNA
03
The spliceosome assembles on both strands
04
RNA is repaired
Why it matters
It is designed to act only where the gene is being transcribed.
The reaction needs a target transcript to work on. In a cell that is not transcribing the gene, there is nothing to act on.
Native regulation is preserved by design.
The cell is still reading its own gene, so it keeps deciding how much protein to make, in which cells, and when.
The size ceiling is designed to move.
Only the replacement portion has to be delivered, so genes too large to fit in a conventional gene-therapy vector come into range.
One design is intended to cover many mutations.
A single Tacit construct is designed to cover many different mutations falling in the same region of a gene.
The discovery engine